Chapter 57. Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders

  1. Frederick R. Appelbaum MD Member Director Professor Head2,3,
  2. Stephen J. Forman MD Director Staff Physician4,5,
  3. Robert S. Negrin MD Professor of Medicine Chief6 and
  4. Karl G. Blume MD, FACP Emeritus Professor of Medicine6,7
  1. H. Joachim Deeg MD Member

Published Online: 5 MAR 2009

DOI: 10.1002/9781444303537.ch57

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

How to Cite

Deeg, H. J. (2009) Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders, in Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition (eds F. R. Appelbaum, S. J. Forman, R. S. Negrin and K. G. Blume), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303537.ch57

Editor Information

  1. 2

    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

  2. 3

    Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USA

  3. 4

    Department of Hematology and Hematopoietic Cell Transplantation, Duarte, California, USA

  4. 5

    Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA

  5. 6

    Division of Blood and Marrow Transplantation, Stanford University, Stanford, California, USA

  6. 7

    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University, School of Medicine, Stanford, California, USA

Author Information

  1. FHCRC Professor of Medicine, University of Washington School of Medicine, Seattle, Washington, USA

Publication History

  1. Published Online: 5 MAR 2009
  2. Published Print: 27 FEB 2009

ISBN Information

Print ISBN: 9781405153485

Online ISBN: 9781444303537

SEARCH

Keywords:

  • Myelodysplastic syndromes (MDSs);
  • allogeneic HCT;
  • hematopoietic cell transplantation for myelodysplastic syndrome and myeloproliferative disorders;
  • World Health Organization classification and criteria for myelodysplastic syndrome (MDS);
  • High-risk MDS;
  • myeloproliferative disorders;
  • scoring systems for myelofibrosis;
  • chronic myelomonocytic leukemia

Summary

This chapter contains sections titled:

  • Introduction

  • General considerations for hematopoietic cell transplantation for MDS and MPD

  • Allogeneic HCT

  • Autologous HCT

  • Relapse after HCT

  • Conclusion

  • Acknowledgments

  • References